News
EXAS
101.06
-0.07%
-0.07
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Benzinga · 2d ago
3 Overrated Stocks That Concern Us
Barchart · 3d ago
Top 2 Health Care Stocks You May Want To Dump This Month
Benzinga · 5d ago
$100 Invested In Exact Sciences 15 Years Ago Would Be Worth This Much Today
Benzinga · 6d ago
Cathie Wood's Ark Invest weekly recap: Boosts AI and Crypto Bets, Trims Palantir, GitLab, and AMD
Seeking Alpha · 6d ago
Weekly Report: what happened at EXAS last week (1124-1128)?
Weekly Report · 6d ago
Cathie Wood Marks Black Friday with Bitcoin ETF Buy and GitLab Stock Sell-Off
TipRanks · 11/29 14:54
Exact Sciences, Regeneron, Marvell, JFrog, Jazz: Trending by Analysts
TipRanks · 11/29 09:00
Exact Sciences downgraded to Hold from Buy at Stifel
TipRanks · 11/28 21:00
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Seeking Alpha · 11/28 18:30
Private Markets: Prediction market platform Kalshi secures $300M
TipRanks · 11/28 15:01
Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 15 Years
Benzinga · 11/25 23:00
EXAS Quantitative Stock Analysis
NASDAQ · 11/25 19:00
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 11/25 17:21
Brinker upgraded, Coinbase downgraded: Wall Street’s top analyst calls
TipRanks · 11/25 14:40
Exact Sciences Price Target Raised to $105.00/Share From $85.00 by Canaccord Genuity
Dow Jones · 11/25 13:29
Exact Sciences Cut to Hold From Buy by Canaccord Genuity
Dow Jones · 11/25 13:29
Canaccord Genuity Downgrades Exact Sciences to Hold, Raises Price Target to $105
Benzinga · 11/25 13:19
U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital
Reuters · 11/25 07:29
EXACT SCIENCES CORP <EXAS.O>: CANACCORD GENUITY CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $105 FROM $85
Reuters · 11/25 06:01
More
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.